Does Blue Cross Blue Shield of Minnesota Cover Prolia?

What Prolia Is and Why Coverage Decisions Are Complex

Prolia is the brand name for denosumab, a human monoclonal antibody that blocks RANK ligand, the protein that activates osteoclasts. By suppressing osteoclast activity, Prolia slows bone resorption and reduces fracture risk. The FDA approved it in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and later expanded the label to include bone loss in men receiving androgen-deprivation therapy for prostate cancer, bone loss in women receiving aromatase inhibitors for breast cancer, and glucocorticoid-induced osteoporosis in adults. [1]

Coverage decisions are complex because Prolia sits at the boundary of the medical and pharmacy benefit. Most commercial insurers, including BCBS MN, administer Prolia under the medical benefit when a physician buys and bills the injection in an office setting. That means the drug goes through different cost-sharing rules than a specialty pharmacy drug would. A patient whose plan has a low specialist copay might pay far less than one whose plan applies a 20% coinsurance to the medical benefit. [2]

The Buy-and-Bill vs. Specialty Pharmacy Distinction

Under the buy-and-bill model, your physician's office orders Prolia directly, administers it, and submits a claim to BCBS MN using the HCPCS code J0897. The insurer reimburses the practice, and the patient pays whatever cost-sharing the medical benefit requires. Under a specialty pharmacy model, the prescription is sent to a contracted pharmacy, and the patient picks up or receives the drug, then brings it to the appointment. The cost-sharing tier for specialty drugs is often higher.

Calling BCBS MN member services (the number on your insurance card) and asking which benefit category Prolia falls under for your specific plan is the single fastest way to get an accurate cost estimate before the first dose.

Why List Price Alone Is Misleading

Prolia's wholesale acquisition cost is approximately $1,393 per injection as of late 2024, which translates to roughly $2,786 per year for the standard two-injection schedule. [3] Patients with active insurance rarely pay the list price, but cost-sharing on the medical benefit can still reach hundreds of dollars per injection if a plan applies a percentage coinsurance rather than a flat copay. Knowing your specific plan's cost-sharing structure matters more than the list price.

Prior Authorization Requirements for Prolia Under BCBS MN

Prior authorization (PA) is nearly universal for Prolia across BCBS MN commercial plans, individual marketplace plans, and Medicare Advantage products. The PA process requires your prescribing physician to submit clinical documentation showing that you meet coverage criteria before BCBS MN will approve the claim.

Typical Clinical Criteria BCBS MN Evaluates

While exact criteria vary by plan year and product line, BCBS MN commercial PA criteria for Prolia typically assess several clinical factors.

Diagnosis confirmation. The plan will want a confirmed diagnosis of osteoporosis or one of the other labeled indications. For postmenopausal osteoporosis, this usually means a bone mineral density (BMD) T-score of -2.5 or lower at the lumbar spine or hip, or a T-score between -1.0 and -2.5 with a documented fragility fracture or high FRAX score. The World Health Organization defines osteoporosis as a T-score at or below -2.5 SD compared with a young adult reference mean. [4]

Prior therapy. Most BCBS MN plans require a documented trial of at least one oral bisphosphonate, typically alendronate 70 mg weekly or risedronate 35 mg weekly, for 3 to 6 months before approving Prolia. Exceptions exist for patients who have a documented intolerance, contraindication (such as severe chronic kidney disease with an estimated GFR < 35 mL/min/1.73m², where oral bisphosphonates carry increased risk), or experienced a fracture while on bisphosphonate therapy.

Prescriber type. Some PA templates specify that the prescribing physician be an endocrinologist, rheumatologist, or another specialist familiar with metabolic bone disease, though primary care physicians can and do obtain PA approvals.

Re-authorization. Approval is generally granted for 12 months (covering two injections). Annual re-authorization requires evidence of ongoing clinical benefit, usually documented as stable or improved BMD on DXA scan.

How to Submit a PA for Prolia

Your physician's office submits the PA through BCBS MN's provider portal or by fax using the drug-specific PA request form. The form typically asks for the ICD-10 diagnosis code (M81.0 for postmenopausal osteoporosis without current pathological fracture is the most common), most recent DXA T-scores with dates, a list of prior osteoporosis medications with start and stop dates, and the reason bisphosphonate therapy is inadequate or contraindicated. BCBS MN is required by Minnesota state law to issue an initial PA determination within 3 business days for non-urgent requests and within 24 hours for urgent requests. [5]

Step Therapy: The Bisphosphonate-First Requirement

Step therapy, sometimes called fail-first, is the requirement that a patient try one or more lower-cost drugs before the insurer will authorize the preferred agent. For Prolia, BCBS MN plans most commonly require a bisphosphonate trial first. This is consistent with national clinical practice guidelines.

What the Guidelines Say

The American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis list denosumab as a Tier 1 agent for patients at very high fracture risk, but note that oral bisphosphonates remain acceptable first-line therapy for most patients at high (but not very high) fracture risk. [6] The Endocrine Society's 2019 Pharmacological Management of Osteoporosis guideline similarly positions bisphosphonates as first-line for most patients and reserves Prolia for situations where bisphosphonates are contraindicated or have failed. [7]

From the AACE 2020 guidelines: "For patients at very high risk of fracture, defined as a recent fracture within 12 months, fracture on therapy, or T-score below -3.0, anabolic therapy or denosumab may be preferred over bisphosphonates as initial treatment." [6]

This means that if your physician can document very high fracture risk using AACE criteria, BCBS MN may approve Prolia without a bisphosphonate trial. Framing the PA request around that clinical threshold is one of the most effective strategies.

Minnesota Step Therapy Protections

Minnesota enacted step therapy reform legislation that limits how insurers can impose step therapy. Under Minnesota Statutes Section 62Q.184, a health plan must grant a step therapy exception when the required drug is contraindicated, clinically ineffective, or will cause an adverse reaction, or when the patient has already tried and failed the required drug. [5] If your prescriber believes bisphosphonate step therapy is clinically inappropriate for you specifically, a formal exception request citing this statute can accelerate approval.

Cost Sharing: What You Might Actually Pay

Out-of-pocket costs for Prolia under BCBS MN depend on your plan type (HMO, PPO, EPO), benefit category (medical vs. Pharmacy), deductible status, and whether you have met your out-of-pocket maximum for the year.

Commercial and Employer-Sponsored Plans

On a typical BCBS MN commercial PPO where Prolia is billed under the medical benefit, a patient who has met their deductible might owe a specialist office visit copay of $50 to $75 per injection visit, with little or no additional drug-specific cost-sharing. A patient who has not met their deductible could owe the full allowed amount for the drug, which varies by plan contract but may be several hundred dollars per injection.

Some BCBS MN plans use a specialty tier with a separate coinsurance of 20% to 30% for high-cost biologics even under the medical benefit. On a 20% coinsurance structure and a $1,200 allowed amount, the patient share would be $240 per injection, or $480 per year.

Medicare Advantage Plans

BCBS MN administers several Medicare Advantage products in Minnesota. Under Medicare, Part B covers Prolia when administered by a physician (not self-administered at home), because the FDA label specifies administration by a healthcare professional. [1] Under a Medicare Advantage plan, the Part B cost-sharing rules apply unless the plan has negotiated a different structure. Standard Medicare Part B cost-sharing is 20% of the Medicare-approved amount after the Part B deductible ($240 in 2024). Medicare Advantage plans may have different copay structures, so reviewing the plan's Evidence of Coverage document is necessary.

Using Amgen's Prolia SupportPlus Program

Amgen, the manufacturer of Prolia, operates the Prolia SupportPlus patient assistance program. Commercially insured patients who qualify may pay as little as $0 per dose through a co-pay card. Patients who are uninsured or who meet income eligibility criteria may receive Prolia at no cost through the Amgen Assist 360 free drug program. The commercial co-pay card cannot be used by Medicare or Medicaid patients, per federal anti-kickback rules. Patients can enroll at amgensupportplus.com or call 1-800-772-6436. [8]

How to Appeal a BCBS MN Prolia Denial

BCBS MN denials for Prolia typically fall into one of three categories: failure to meet clinical criteria, step therapy not completed, or missing documentation. Each is addressable on appeal.

Step 1: Request the Denial Letter and Coverage Criteria

BCBS MN is required to provide a written denial letter explaining the specific reason for denial and citing the criteria used. Request the full clinical coverage criteria document referenced in the denial. Reviewing the exact language of those criteria tells your physician's office precisely what documentation gap needs to be filled.

Step 2: File an Internal Appeal

An internal appeal asks BCBS MN to reconsider the PA decision. In Minnesota, health plans must decide a standard internal appeal within 30 days. The appeal should include a letter from your physician explaining the clinical rationale for Prolia, updated DXA results, a medication history showing prior bisphosphonate use or contraindication, and any relevant peer-reviewed literature. A 2019 analysis published in JAMA Internal Medicine found that patients who appealed insurance denials for specialty drugs succeeded in overturning the denial in approximately 39% of cases. [9]

Step 3: Request an Independent External Review

If the internal appeal is denied, Minnesota residents have the right to an independent external review under Minnesota Statutes Section 62Q.73. An independent review organization (IRO) not affiliated with BCBS MN will evaluate the case. IRO decisions are binding on the health plan. External review requests must generally be filed within 4 months of the internal appeal denial. [5]

Step 4: File a Complaint with the Minnesota Department of Commerce

The Minnesota Department of Commerce oversees health insurance in the state. Filing a complaint does not guarantee reversal, but it creates a formal record and may prompt expedited review. Complaints can be submitted online at mn.gov/commerce or by calling 651-539-1500.

Clinical Evidence Supporting Prolia for Osteoporosis

Understanding the clinical evidence helps your physician write a stronger PA letter and helps you have an informed conversation about whether Prolia is the right choice.

The FREEDOM Trial

The key phase 3 FREEDOM trial (N=7,868 postmenopausal women with osteoporosis, T-score between -2.5 and -4.0 at lumbar spine or total hip) showed that denosumab 60 mg every 6 months for 36 months reduced the risk of new vertebral fracture by 68% compared with placebo (P<0.001), nonvertebral fracture by 20% (P<0.001), and hip fracture by 40% (P=0.04). [10] These are large effect sizes. The FREEDOM Extension study followed participants for a total of 10 years and showed sustained BMD gains and continued fracture risk reduction without a plateau. [11]

The FREEDOM Extension: Long-Term Safety Signal

One clinically relevant finding from FREEDOM Extension is that discontinuing Prolia without transitioning to an antiresorptive agent leads to rapid bone loss and a potential rebound increase in vertebral fracture risk, sometimes called rebound-associated vertebral fractures (RAVF). A 2019 case series published in Osteoporosis International identified multiple vertebral fractures within 12 to 18 months of Prolia discontinuation in patients who did not receive bridging antiresorptive therapy. [12] This is relevant for coverage decisions because it argues against stopping Prolia once started, which strengthens the clinical case for continued authorization.

Fracture Efficacy in Context

The National Osteoporosis Foundation estimates that 10 million Americans have osteoporosis and another 44 million have low bone density, placing them at increased fracture risk. [13] Hip fractures carry a 1-year mortality rate of approximately 20 to 24% in older adults. [14] These numbers give physicians a strong clinical argument when writing PA letters: the consequences of undertreating osteoporosis are severe enough to justify a higher-cost agent in appropriate patients.

Practical Steps Before Your First Prolia Injection

Taking the right steps before the first dose protects you from surprise bills and treatment delays.

Verify Your Specific Plan's Coverage

Call the member services number on your BCBS MN insurance card. Ask specifically: Is Prolia covered under my plan? Is it billed under the medical or pharmacy benefit? Does it require prior authorization? What is my cost-sharing for a specialty medical benefit drug? Note the date, time, and name of the representative.

Ask Your Physician's Office to Verify Benefits

Physician offices that regularly administer Prolia typically have billing staff experienced with PA submissions. Ask whether the office will submit the PA on your behalf, or whether you need to take additional steps. Most offices handle this routinely, but confirming the workflow prevents delays.

Confirm DXA Documentation Is Current

BCBS MN PA criteria almost always require a recent DXA scan. If your last DXA was more than 2 years ago, scheduling an updated scan before the PA submission gives the reviewer the most current T-score data and reduces the chance of a documentation-based denial. The U.S. Preventive Services Task Force recommends bone density screening for women 65 and older and for younger postmenopausal women with clinical risk factors. [15]

Check Dental Health Before Starting

Denosumab carries a class warning for osteonecrosis of the jaw (ONJ), a rare but serious complication that occurs more commonly in patients who undergo invasive dental procedures while on therapy. The American Dental Association recommends that patients complete any necessary invasive dental work before starting Prolia and maintain routine oral hygiene throughout treatment. [16] BCBS MN's PA process does not require dental clearance, but your prescribing physician should discuss this risk during the informed consent conversation.